Drugs in Context (Sep 2024)

Rapid Efficacy of riSankizumab in pretibial psoriasis invOLVEment: RESOLVE

  • Nicoletta Bernardini,
  • Nevena Skroza,
  • Laura Atzori,
  • Cristina Mugheddu,
  • Matteo Megna,
  • Sara Cacciapuoti,
  • Michela Ortoncelli,
  • Maria A Montesu,
  • Antonio Carpentieri,
  • Martino Carriero,
  • Maria G Atzori,
  • Gianmario Addis,
  • Riccardo Balestri,
  • Giulia Rech,
  • Pierluigi Bruni,
  • Manuela Papini,
  • Concetta Potenza

DOI
https://doi.org/10.7573/dic.2024-6-3
Journal volume & issue
Vol. 13
pp. 1 – 8

Abstract

Read online

Background: Despite extraordinary improvements in the management of psoriasis in recent times, some areas of the body, such as the pretibial area, still show an unsatisfactory response and a more significant impact on patient quality of life. This multicentre study focuses on psoriasis affecting sensitive areas (particularly the pretibial area), its impact on quality of life and the therapeutic response to risankizumab. Methods: This multicentre prospective observational study recruited patients with moderate-to-severe psoriasis with pretibial area involvement. All patients underwent treatment with risankizumab (150 mg every 3 weeks), and efficacy was assessed after 24 weeks. Results: The study included 128 patients with a mean age of 51 years, suffering from moderate-to-severe psoriasis with involvement of the pretibial area with median total Psoriasis Area Severity Index score of 17.05 and Dermatology Life Quality Index of 16.27. The group was further divided into two sub-groups: the ‘mother patch’ group, in whom the very first psoriatic plaque appeared in the pretibial region (45 patients), and the ‘non-mother patch’ group, in whom the psoriatic lesion in the pretibial region was present but not as the first manifestation (83 patients). In order to better assess the involvement of psoriasis in the pretibial area, the pretibial plaque lesion severity index was also calculated at baseline in all patients: extent 2.75, erythema 2.64, infiltration 2.45 and desquamation 2.38. All participants in this study showed a good therapeutic response, with a reduction in all scores. Conclusions: The pretibial area is becoming an object of therapeutic interest due to some resistance to clearance and the consequent impairment of patient quality of life. This study showed that risankizumab can give favourable therapeutic results not only in patients with moderate-to-severe psoriasis with involvement of the difficult-to-treat areas but particularly in patients with recalcitrant plaques in the pretibial area.

Keywords